Oblato, Inc. Report issue

For profit Phase 2
Founded: Princeton NJ United States (2015)

Organization Overview

First Clinical Trial
2015
NCT01672463
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Oblato, Inc.